SCHEMBL4993201

SCHEMBL4993201

CCOC(=O)c1cccn(Cc2ccccc2C(C)C)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.53
LMNA P02545 3/20 0.53
RXFP1 Q9HBX9 3/20 0.53
TSHR P16473 1/20 0.47
MAPT P10636 8/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 4/20 0.45
GAA P10253 3/20 0.45
HPGD P15428 2/20 0.45
GLA P06280 1/20 0.45
HSD17B10 Q99714 2/20 0.45
NPSR1 Q6W5P4 2/20 0.43
THRB P10828 1/20 0.42
BRD4 O60885 2/20 0.42
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BRDT Q58F21 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX2 P34913 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4438870 0.91 LMNA (0.49) TP53LMNARXFP1TSHRMAPT
SCHEMBL4993505 0.84 BRD4 (0.48) TP53LMNARXFP1MAPTKDM4E
SCHEMBL4991532 0.82 LMNA (0.48) TP53LMNARXFP1TSHRMAPT
SCHEMBL4994979 0.80 LMNA (0.46) TP53LMNARXFP1TSHRMAPT
SCHEMBL739464 0.77 TSHR (0.71) LMNATSHRMAPTALDH1A1KDM4E
SCHEMBL25075372 0.77 TSHR (0.50) TP53LMNARXFP1TSHRMAPT
SCHEMBL29168930 0.77 TSHR (0.50) TP53LMNARXFP1TSHRMAPT
SCHEMBL4989937 0.77 MAPT (0.46) TP53LMNARXFP1MAPTALDH1A1
SCHEMBL19787912 0.76 MAPT (0.54) TP53LMNARXFP1TSHRMAPT
SCHEMBL4986594 0.76 LMNA (0.48) TP53LMNARXFP1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 TP53 3536/4885LMNA 809/4885RXFP1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.